# Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

Study · id `cardio:ct-nct05004675` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05004675](<https://clinicaltrials.gov/study/NCT05004675>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05004675

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

## Technical summary

Registry record NCT05004675. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-20 (actual); primary completion 2024-05-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 166 participants (enrolled count; ClinicalTrials.gov record NCT05004675, source copy `cardio:ctgov-nct05004675-2024-10-23`, retrieved 2026-10-31)
- Started: 2022-06-20 (actual) (ClinicalTrials.gov record NCT05004675, source copy `cardio:ctgov-nct05004675-2024-10-23`, retrieved 2026-10-31)
- Primary completion: 2024-05-30 (actual) (ClinicalTrials.gov record NCT05004675, source copy `cardio:ctgov-nct05004675-2024-10-23`, retrieved 2026-10-31)
- Completion: 2024-10-15 (actual) (ClinicalTrials.gov record NCT05004675, source copy `cardio:ctgov-nct05004675-2024-10-23`, retrieved 2026-10-31)
- Countries: France; Germany; Norway; Spain; United Kingdom (ClinicalTrials.gov record NCT05004675, source copy `cardio:ctgov-nct05004675-2024-10-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05004675-2024-10-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
- Acronym: LIBerate-VI
- Condition: Hypercholesterolemia
- Condition: Atherosclerotic Ischemic Disease
- Intervention (Biological): lerodalcibep
- Intervention (Drug): Inclisiran
- Lead sponsor: LIB Therapeutics LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: LIB Therapeutics LLC (`cardio:org-lib-therapeutics-llc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

## Provenance

Content hash: 23bc366c255af64386c51abc71453ca7f6339b6a4135449b3c44e16ed676af41
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
